General
Preferred name
TELATINIB
Synonyms
BAY-57-9352, BAY-579352 ()
Bay 57-9352 ()
Telatinib (BAY 57-9352) ()
BAY-57-9352 ()
Telatinib (mesylate) ()
Bay 57-9352 (mesylate) ()
BAY-579352 ()
BAY 57-9352 ()
P&D ID
PD010812
CAS
332012-40-5
332013-26-0
Tags
available
drug candidate
Drug indication
Gastric adenocarcinoma
Neoplasm
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Telatinib (BAY-579352) is an orally available VEGFR2/3 and PDGFRβ receptor tyrosine kinase inhibitor that exhibits potent anti-angiogenic activity which translates to anti-tumour efficacy in vitro and in vivo. The chemical structure of telatinib is claimed in Bayer's patent WO2001023375A2 (as example 14) . (GtoPdb)
PRICE 29
DESCRIPTION Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGF¦Á, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively.
DESCRIPTION Telatinib (Bay 57-9352) is an effective inhibitor of VEGFR2/3, c-Kit, and PDGFR??, with IC50s of 6 nM/4 nM, 1 nM, and 15 nM, respectively.
DESCRIPTION Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2, VEGFR3, PDGF¦Á, and c-Kit inhibitor with IC50s of 6 nM, 4 nM, 15 nM and 1 nM, respectively[1].
DESCRIPTION Telatinib is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. (BOC Sciences Bioactive Compounds)
DESCRIPTION Telatinib (Bay 57-9352) is an effective inhibitor of VEGFR2/3, c-Kit, and PDGFRα, with IC50s of 6 nM/4 nM, 1 nM, and 15 nM, respectively. (TargetMol Bioactive Compound Library)
Compound Sets
18
AdooQ Bioactive Compound Library
A10903
BOC Sciences Bioactive Compounds
telatinib-cas-332012-40-5-item-108953
Cayman Chemical Bioactives
26203
ChEMBL Drugs
CHEMBL2079588
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DB15393
DrugMAP
DMVA5NS
EU-OPENSCREEN Bioactive Compound Library
EOS100970
Guide to Pharmacology
10476
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL2079588
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL2079588
MedChem Express Bioactive Compound Library
HY-10527
HY-10527C
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
Telatinib-BAY-57-9352
TargetMol Bioactive Compound Library
T6166
ZINC Tool Compounds
ZINC000000590964
External IDs
32
Properties
(calculated by RDKit )
Molecular Weight
409.09
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
4
cLogP
3.95
TPSA
102.17
Fraction CSP3
0.1
Chiral centers
0.0
Largest ring
6.0
QED
0.5
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
KDR,FLT4,KIT
Target
c-Kit
PDGFR
PDGFRα
VEGFR
VEGFR2
VEGFR3
KDR
c-Kit,PDGFR,VEGFR
FLT4
MOA
KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Therapeutic Class
Anticancer Agents
Source data